Suzanne Patton, MD

Articles by Suzanne Patton, MD

Irinotecan/Gemcitabine Followed by Twice-Weekly Gemcitabine/Radiation in Locally Advanced Pancreatic Cancer

ByA. William Blackstock, Jr, MD,Susan A. Melin, MD,Jerome M. Butler, MD,Suzanne Patton, MD,Benjamin Pineau, MD,David Albertson, MD,Russell Howerton, MD,Edward Levine, MD

May 2nd 2002

Early clinical studies combining irinotecan (CPT-11, Camptosar) and gemcitabine (Gemzar) have yielded encouraging results. Gemcitabine administered via a twice-weekly schedule results in an enhanced radiation-sensitizing effect.

Latest Updated Articles

Irinotecan/Gemcitabine Followed by Twice-Weekly Gemcitabine/Radiation in Locally Advanced Pancreatic Cancer
Published: May 2nd 2002 | Updated:

Suzanne Patton, MD

Articles by Suzanne Patton, MD

Irinotecan/Gemcitabine Followed by Twice-Weekly Gemcitabine/Radiation in Locally Advanced Pancreatic Cancer

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment